Journal
ALZHEIMERS & DEMENTIA
Volume 9, Issue 5, Pages 602-608Publisher
WILEY
DOI: 10.1016/j.jalz.2012.12.001
Keywords
Neuropsychiatric symptoms; Behavioral and psychological symptoms of dementia; Agitation/aggression; Sleep disorders; Depression; Apathy; Psychosis; Delusions; Hallucinations; Dementia; Alzheimer's disease; Mild cognitive impairment; Mild behavioral impairment
Categories
Funding
- NIMH [K01-MH68351, R24-MH074779, R01-MH079814, RC1-MH090770-01]
- NIA [U01-AG006786]
- National Center for Research Resources [RR024150]
- Robert Wood Johnson Foundation
- European Union Regional Development Fund [FNUSA-ICRC: CZ.1.05/1.1.00/02.0123]
- Baxter
- Elan Pharmaceuticals
- Johnson Johnson
- Eli Lilly
- Myriad
- Novartis
- Pfizer
- Abbott Laboratories
- AC Immune
- Allergan
- Allon
- Alzheimer Drug Discovery Foundation
- AstraZeneca
- Bristol-Myers Squibb
- Elan
- Exonhit
- Forest
- GlaxoSmithKline
- Ipsen Pharmaceuticals
- Lundbeck
- Medavante
- Medivation
- Merck
- Merz
- Roche
- Sanofi-Aventis
- Schering-Plough
- Schwabe
- Toyama
- Transition Therapeutics
- Alzheimer's Association [IIRG-07-28686]
- Johns Hopkins Alzheimer's Disease Research Center [P50-AG005146]
- NIMH, MA
- Associated Jewish Federation of Baltimore
- Weinberg Foundation
- Eisai
- Lilly
- Ortho-McNeil
- Bristol-Myers
- National Football League
- Functional Neuromodulation Inc.
Ask authors/readers for more resources
Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis. (C) 2013 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
